Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.K. (FTSE) Healthcare Sector Analysis

UpdatedSep 23, 2025
DataAggregated Company Financials
Companies88
  • 7D0.09%
  • 3M6.8%
  • 1Y-2.1%
  • YTD6.8%

The Healthcare industry has been flat over the last week, but Haleon has lost 6.8%. In line with that, the industry has also been flat over the past 12 months. Looking forward, earnings are forecast to grow by 14% annually.

Sector Valuation and Performance

Has the U.K. Healthcare Sector valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Tue, 23 Sep 2025UK£304.1bUK£100.8bUK£12.1b28.4x25.2x3x
Thu, 21 Aug 2025UK£315.1bUK£100.9bUK£12.0b29.2x26.2x3.1x
Sat, 19 Jul 2025UK£280.0bUK£99.8bUK£10.9b31.5x25.6x2.8x
Mon, 16 Jun 2025UK£298.4bUK£96.8bUK£10.7b29.7x27.9x3.1x
Wed, 14 May 2025UK£278.5bUK£97.9bUK£10.9b30.1x25.7x2.8x
Fri, 11 Apr 2025UK£267.1bUK£98.3bUK£9.8b27.9x27.3x2.7x
Sun, 09 Mar 2025UK£317.2bUK£98.5bUK£9.6b27.1x33.1x3.2x
Tue, 04 Feb 2025UK£298.4bUK£97.9bUK£8.9b28.2x33.4x3x
Thu, 02 Jan 2025UK£246.5bUK£86.1bUK£7.7b31.3x32.2x2.9x
Sat, 30 Nov 2024UK£249.2bUK£85.4bUK£7.6b27.7x32.8x2.9x
Mon, 28 Oct 2024UK£270.2bUK£83.0bUK£8.9b25.5x30.2x3.3x
Wed, 25 Sep 2024UK£272.3bUK£81.3bUK£8.8b28.8x31.1x3.4x
Fri, 23 Aug 2024UK£299.1bUK£82.3bUK£8.9b34.2x33.6x3.6x
Sun, 21 Jul 2024UK£281.0bUK£81.0bUK£9.3b32.4x30.2x3.5x
Tue, 18 Jun 2024UK£288.0bUK£81.7bUK£9.4b30.8x30.6x3.5x
Thu, 16 May 2024UK£294.5bUK£81.8bUK£9.4b33.8x31.3x3.6x
Sat, 13 Apr 2024UK£271.0bUK£81.8bUK£9.7b29.9x28x3.3x
Mon, 11 Mar 2024UK£259.9bUK£80.2bUK£9.5b34.5x27.3x3.2x
Wed, 07 Feb 2024UK£262.0bUK£79.1bUK£9.4b36.6x27.9x3.3x
Fri, 05 Jan 2024UK£277.6bUK£84.0bUK£10.7b41.3x26.1x3.3x
Sun, 03 Dec 2023UK£261.8bUK£84.0bUK£10.7b39x24.6x3.1x
Tue, 31 Oct 2023UK£263.7bUK£86.0bUK£10.3b40.1x25.6x3.1x
Thu, 28 Sep 2023UK£282.3bUK£86.2bUK£10.3b39.9x27.3x3.3x
Sat, 26 Aug 2023UK£270.2bUK£84.5bUK£10.2b40.4x26.5x3.2x
Mon, 24 Jul 2023UK£273.7bUK£82.1bUK£7.8b46.6x34.9x3.3x
Wed, 21 Jun 2023UK£285.0bUK£82.4bUK£7.9b46.9x36.2x3.5x
Fri, 19 May 2023UK£293.7bUK£83.6bUK£8.0b46.7x36.8x3.5x
Sun, 16 Apr 2023UK£295.7bUK£84.3bUK£6.9b46.4x42.8x3.5x
Tue, 14 Mar 2023UK£268.8bUK£85.1bUK£6.9b41.3x38.8x3.2x
Thu, 09 Feb 2023UK£278.7bUK£86.0bUK£6.6b36.8x42.3x3.2x
Sat, 07 Jan 2023UK£291.4bUK£95.3bUK£6.6b36.5x44.1x3.1x
Mon, 05 Dec 2022UK£280.6bUK£94.6bUK£6.6b36.9x42.6x3x
Wed, 02 Nov 2022UK£266.0bUK£95.5bUK£4.0b30.2x66.4x2.8x
Fri, 30 Sep 2022UK£252.8bUK£97.4bUK£4.0b27.9x63.4x2.6x
Price to Earnings Ratio

63.4x


Total Market Cap: UK£252.8bTotal Earnings: UK£4.0bTotal Revenue: UK£97.4bTotal Market Cap vs Earnings and Revenue0%0%0%
U.K. Healthcare Sector Price to Earnings3Y Average 35.2x202320242025
Current Industry PE
  • Investors are pessimistic on the British Healthcare industry, indicating that they anticipate long term growth rates will be lower than they have historically.
  • The industry is trading at a PE ratio of 25.2x which is lower than its 3-year average PE of 35.2x.
  • The industry is trading close to its 3-year average PS ratio of 3.3x.
Past Earnings Growth
  • The earnings for companies in the Healthcare industry have grown 45% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the U.K. Healthcare sector?

GB Market-0.48%
Healthcare0.09%
Healthcare Services2.92%
Pharma0.16%
Biotech0.0025%
Life Sciences-0.047%
Medical Equipment-1.58%
Healthtech-2.65%
Industry PE
  • Investors are most optimistic about the Healthtech industry which is trading above its 3-year average PE ratio.
    • Analysts are expecting annual earnings growth of 16.8%, which is lower than the prior year's growth of 68.0% per year.
Forecasted Growth
  • Analysts are most optimistic on the Life Sciences industry, expecting annual earnings growth of 39% over the next 5 years.
  • This is better than its past earnings decline of 34% per year.
  • In contrast, the Pharma industry is expected to see its earnings grow by 13% per year over the next few years.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
AZN AstraZenecaUK£115.000.8%
+UK£1.3b		-0.7%PE29.1x
GSK GSKUK£15.112.2%
+UK£1.3b		-1.1%PE17.8x
SPI Spire Healthcare GroupUK£2.3613.2%
+UK£110.7m		0.9%PE51.2x
HIK Hikma PharmaceuticalsUK£16.331.6%
+UK£57.6m		-12.8%PE13.2x
OXB Oxford BiomedicaUK£6.306.2%
+UK£44.5m		75.0%PS5.9x

Latest News

AZN
UK£115.00
AstraZeneca
7D
0.8%
1Y
-0.7%
HCM
UK£2.45
HUTCHMED (China)
7D
-2.0%
1Y
-3.2%

Is HUTCHMED (China) (LON:HCM) Using Debt Sensibly?

Sep 22
Is HUTCHMED (China) (LON:HCM) Using Debt Sensibly?
AMS
UK£2.14
Advanced Medical Solutions Group
7D
5.2%
1Y
-7.0%

Here's What Analysts Are Forecasting For Advanced Medical Solutions Group plc (LON:AMS) After Its Interim Results

Sep 21
Here's What Analysts Are Forecasting For Advanced Medical Solutions Group plc (LON:AMS) After Its Interim Results
SPI
UK£2.36
Spire Healthcare Group
7D
13.2%
1Y
0.9%

Returns On Capital Are Showing Encouraging Signs At Spire Healthcare Group (LON:SPI)

Sep 21
Returns On Capital Are Showing Encouraging Signs At Spire Healthcare Group (LON:SPI)
SN.
UK£13.50
Smith & Nephew
7D
-2.6%
1Y
17.2%

Orthopaedic Solutions And Wound Management Will Expand Global Reach

The significant drop in Smith & Nephew’s future P/E ratio suggests improving earnings expectations or a lower valuation premium, which supports the slight increase in the consensus analyst price target from £13.61 to £13.85. What's in the News AAOS guidelines now strongly recommend Smith & Nephew's REGENETEN Bioinductive Implant for rotator cuff repair, citing significantly lower re-tear rates and improved patient outcomes; new US indication covers extra-articular ligament injuries, expanding the addressable market.
GSK
UK£15.11
GSK
7D
2.2%
1Y
-1.1%

Market Cool On GSK plc's (LON:GSK) Earnings

Sep 19
Market Cool On GSK plc's (LON:GSK) Earnings
CRW
UK£22.50
Craneware
7D
-3.4%
1Y
-2.2%
HLN
UK£3.33
Haleon
7D
-6.8%
1Y
-15.9%

Haleon (LON:HLN) Seems To Use Debt Quite Sensibly

Sep 15
Haleon (LON:HLN) Seems To Use Debt Quite Sensibly
GNS
UK£24.40
Genus
7D
-3.0%
1Y
30.9%
OXB
UK£6.30
Oxford Biomedica
7D
6.2%
1Y
75.0%

CDMO Expansion Will Widen Global Cell And Gene Therapy Access

Analysts have raised Oxford Biomedica’s price target from £5.55 to £5.93, citing improved growth prospects, commercial execution, and operational strength, with ongoing share price weakness seen as a potential entry point despite lingering market uncertainties and execution risks. Analyst Commentary Bullish analysts cite an improved growth outlook and enhanced commercial execution as key drivers for the upward price target revision.
HIK
UK£16.33
Hikma Pharmaceuticals
7D
1.6%
1Y
-12.8%

Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?

Sep 10
Do Hikma Pharmaceuticals' (LON:HIK) Earnings Warrant Your Attention?
CTEC
UK£2.32
ConvaTec Group
7D
-0.09%
1Y
5.2%

Returns On Capital Are Showing Encouraging Signs At ConvaTec Group (LON:CTEC)

Sep 10
Returns On Capital Are Showing Encouraging Signs At ConvaTec Group (LON:CTEC)
IMM
UK£0.11
ImmuPharma
7D
-37.2%
1Y
525.4%
PRTC
UK£1.25
PureTech Health
7D
11.6%
1Y
-11.7%
CVSG
UK£12.68
CVS Group
7D
3.6%
1Y
8.6%
4BB
UK£7.20
4basebio
7D
-14.3%
1Y
-48.6%